[{"id":"327d035e-6791-48a9-8a00-0f3e26e29fa5","acronym":"NeoBRAF","url":"https://clinicaltrials.gov/study/NCT05510895","created_at":"2022-08-22T13:04:27.440Z","updated_at":"2025-02-25T16:18:05.205Z","phase":"Phase 2","brief_title":"Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer","source_id_and_acronym":"NCT05510895 - NeoBRAF","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" BRAF • TRG","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • TRG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2023-06-14"}]